Yolanda Lawson
Obstetrics & Gynecology · Dallas, TXNPI 1912926312
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Viiv Healthcare Company at 38.8% of the total. Reporting peaked in 2023 at $30,617 and has fallen 58.8% since, to $12,610 in 2025. Among obstetrics & gynecology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $407.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$37K
- Pfizer$23K
- Gilead$20K
- Eisai Inc.$4K
- Novartis$2K
- Myovant Sciences Inc.$2K
- plus $7K from 32 others
Across 17 payments — averaging $3135.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$53K
What the payments were for
- Consulting fees$51,31154%
- Speaking & faculty fees$26,76028%
- Travel & lodging$10,17611%
- Food & beverage$7,5298%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 64 | $37,177 |
| Pfizer | 13 | $23,177 |
| Gilead | 22 | $19,539 |
| Eisai Inc. | 3 | $4,247 |
| Novartis | 6 | $2,479 |
| Myovant Sciences Inc. | 7 | $2,146 |
| AbbVie(2 entities) | 41 | $1,849 |
| Scynexis, Inc. | 8 | $1,261 |
| AMAG Pharmaceuticals, Inc. | 4 | $829 |
| Coloplast | 1 | $655 |
| Gynesonics, Inc. | 2 | $555 |
| Ferring Pharmaceuticals Inc. | 1 | $257 |
| Novo Nordisk | 2 | $223 |
| Sage Therapeutics, LLC | 2 | $178 |
| Bayer | 9 | $139 |
| AstraZeneca | 1 | $124 |
| Merck | 7 | $114 |
| Lundbeck LLC | 6 | $103 |
| Organon | 5 | $81 |
| Mylan Pharmaceuticals Inc. | 4 | $80 |
| Regeneron Healthcare Solutions, Inc. | 1 | $79 |
| Lupin Inc. | 4 | $74 |
| Therapeuticsmd, Inc. | 3 | $50 |
| Evofem Biosciences, Inc. | 2 | $47 |
| Exeltis, USA Inc. | 2 | $41 |
| Avion Pharmaceuticals | 3 | $40 |
| Mayne Pharma Commercial LLC | 1 | $38 |
| Johnson & Johnson | 1 | $22 |
| Millicent US Inc | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Agile Therapeutics, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Minerva Surgical, Inc | 1 | $17 |
| Covidien LP | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Acessa Health Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAXLOVID$11,964
- APRETUDE$6,825
- DOVATO$6,500
- Yeztugo$1,860
- MYFEMBREE$1,525
- MAKENA$636
- Sonata System$555
- CABENUVA$256
- Descovy$250
- Orilissa$233
- Ozempic$125
- FASENRA$124
- PREVNAR - 13$124
- PREVNAR 20$124
How this compares
$95,776 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Other obstetrics & gynecology in Dallas
- Dale StovallDallas$590K
- Quanita CrableDallas$176K
- Kamilia SmithDallas$119K
- Patrick WeixDallas$96K
- David RogersDallas$44K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
- Catherine HansenWebster$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.